Geron spikes after Q3 beat and $375M funding deal

seekingalpha11-07

mohd izzuanGeron (NASDAQ:GERN) shares traded higher in the premarket on Thursday after the company reported better-than-expected earnings for Q3 and announced a $375M funding deal with Royalty Pharma ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481090235?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2155546196/image_2155546196.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-11-07 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481090235","market":"nz","top_or_hot":-1,"title":"Geron spikes after Q3 beat and $375M funding deal","media":"seekingalpha","content":"<div>\n<p>mohd izzuanGeron (NASDAQ:GERN) shares traded higher in the premarket on Thursday after the company reported better-than-expected earnings for Q3 and announced a $375M funding deal with Royalty Pharma ...</p>\n\n<a href=\"https://seekingalpha.com/news/4260409-geron-stock-spikes-q-3-beat-funding-deal\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Geron spikes after Q3 beat and $375M funding deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeron spikes after Q3 beat and $375M funding deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 20:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4260409-geron-stock-spikes-q-3-beat-funding-deal><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>mohd izzuanGeron (NASDAQ:GERN) shares traded higher in the premarket on Thursday after the company reported better-than-expected earnings for Q3 and announced a $375M funding deal with Royalty Pharma ...</p>\n\n<a href=\"https://seekingalpha.com/news/4260409-geron-stock-spikes-q-3-beat-funding-deal\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://seekingalpha.com/news/4260409-geron-stock-spikes-q-3-beat-funding-deal","article_id":"2481090235","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2155546196/image_2155546196.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481090235","pubTimestamp":1730982855,"columns":[],"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"mohd izzuanGeron  shares traded higher in the premarket on Thursday after the company reported better-than-expected earnings for Q3 and announced a $375M funding deal with Royalty Pharma  and investment manager Pharmakon Advisors. Foster City, California-based biotech’s Q3 beat was driven by its newly launched blood disorder therapy Rytelo, which added $28.2M to the topline during its first full quarter of U.S. launch. “The initial full quarter of product revenue from our U.S. launch exceeded our expectations and demonstrates strong execution as a commercial company,” said CEO John Scarlett. Meanwhile, GERN’s net loss narrowed ~41% YoY to $26.4M as the company cut its R&D expenses by ~31% YoY to $20.2M. As for guidance, Geron  lowered its full-year outlook for total operating expenses to $ 260M-$270M from $270M-$280M projected three months ago. As part of the funding agreement, GERN said Royalty Pharma  is expected to provide the company with $125M in cash upfront in exchange for a syn","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","GERN":"杰龙","SQQQ":"纳指三倍做空ETF","QID":"纳指两倍做空ETF","RPRX":"Royalty Pharma plc","QLD":"纳指两倍做多ETF",".IXIC":"NASDAQ Composite","PSQ":"纳指反向ETF","BK4139":"生物科技","TQQQ":"纳指三倍做多ETF"},"translate_title":"Geron在第三季度业绩和3.75亿美元融资交易后股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GERN":1,"RPRX":1,".IXIC":0.61,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"mohd izzuanGeron (NASDAQ:GERN) shares traded higher in the premarket on Thursday after the company reported better-than-expected earnings for Q3 and announced a $375M funding deal with Royalty Pharma (RPRX) and investment manager Pharmakon Advisors. Foster City, California-based biotech’s Q3 beat was driven by its newly launched blood disorder therapy Rytelo, which added $28.2M to the topline during its first full quarter of U.S. launch. “The initial full quarter of product revenue from our U.S. launch exceeded our expectations and demonstrates strong execution as a commercial company,” said CEO John Scarlett. Meanwhile, GERN’s net loss narrowed ~41% YoY to $26.4M as the company cut its R&D expenses by ~31% YoY to $20.2M. As for guidance, Geron (NASDAQ:GERN) lowered its full-year outlook for total operating expenses to $ 260M-$270M from $270M-$280M projected three months ago. As part of the funding agreement, GERN said Royalty Pharma (RPRX) is expected to provide the company with $125M in cash upfront in exchange for a synthetic royalty on U.S. sales of Rytelo. Meanwhile, investment funds managed by Pharmakon Advisors are set to provide $250M as part of a 5-year, senior secured term loan. The company has already received its first tranche of $125M.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481090235"}